52
THE FUTURE OF NON THERMAL ABLATION: IS THE FUTURE OF ENDOVENOUS ABLATION STEVE ELIAS MD FACS DIRECTOR, CENTER FOR VEIN DISEASE DIRECTOR, WOUND CARE CENTER ENGLEWOOD HOSPITAL AND MEDICAL CENTER NJ

Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Embed Size (px)

DESCRIPTION

By: Steve Elias, MD, FACS Visit VeinGlobal at http://www.veinglobal.com/ for more presentations and videos on this topic, or for more information on venous disease news, education and research.

Citation preview

Page 1: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

THE FUTURE OF NON THERMAL ABLATION:IS THE FUTURE OF ENDOVENOUS ABLATION

STEVE ELIAS MD FACS DIRECTOR, CENTER FOR VEIN DISEASE

DIRECTOR, WOUND CARE CENTERENGLEWOOD HOSPITAL AND MEDICAL CENTER NJ

Page 2: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Disclosures

• Covidien Inc. – Medical Advisory Board

• Vascular Insights LLC – Medical Advisory Board

• Le Maitre Vascular – Consultant

• VVT Medical - Consultant

Page 3: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

“SO WE BEAT ON, BOATS AGAINST THE CURRENT,

BORNE BACK CEASELESSLY INTO THE PAST”

F. SCOTT FITZGERALD “THE GREAT GATSBY”

Page 4: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

GSV/SSV/AAGSV incompetence (anything straight)

Replaced stripping of great or small saphenous vein

Local/IV Sedation

GSV/SSV/AAGSV incompetence (anything straight)

Replaced stripping of great or small saphenous vein

Local/IV Sedation

Endovenous Ablation 2014:Laser, RF, Mechanochemical, Foam,

Glue, Steam, V Block

Page 5: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

New Technologies: Two New Categories*

• TT (Thermal, Tumescent)

• NTNT (Non Thermal, Non Tumescent)

*Elias S. Emerging Endovenous Technologies. Endovasc Today. March 2014.

Page 6: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Thermal Tumescent: TT

• Laser – HSLW, WSLW, radial/jacketed

• Radiofrequency – Closurefast, RFITT

• Steam – SVS, Veneti

Page 7: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Non Thermal, Non Tumescent: NTNT

• Mechanochemical – ClariVein

• Cyanoacrylate glue – Sapheon

• Polidocanol Endovenous Microfoam – BTG

• V Block – VVT Medical

Page 8: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

CAG (Cyanoacrylate): NTNT

Page 9: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Pollak JS, JVIR, 2001

Permitted for use in endovascular procedures in Europe for several decades

FDA approved in U.S. 2000 Trufill CA (Cordis, Miami, FL) clearance for treatment of cerebral AVMs

CAG: NTNT

Page 10: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Pollak JS, JVIR, 2001Levrier O, J

Neuroradiol 2003

Anionic substances such as plasma or blood polymerization of the adhesive upon contact, leading to occlusion

When introduced within a vessel triggers an acute inflammatory reaction in the wall and surrounding tissues

The resultant polymerization damages the vascular intima and induces immunological responses

CAGCAG: NTNT

Page 11: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

CAG: TREATMENT

Page 12: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Mean max SFJ diameter was 8.0 mm (range 4.1 – 12.0) before treatment

Mean length ablated GSV 33cm (range 15-52)

Mean treatment time 20.3 minutes (range 11 – 33) Mean volume of CA 1.3 ml (range 0.63 - 2.25) 

CAG Dominican Republic: Almeida

Almeida JI, AVF 2012

Page 13: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

DR 30At 6 month:

28/30 (93%) closed 2 re-canalized > 5 cm

X= 1.12cc

DR 8All original 8 closed at 1-yearX= 1.58cc

CAG Efficacy

Almeida JI, AVF 2012

Page 14: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

CAG: First Results

• 38 pts.• No compression/No tumescence• 1° Endpoint – safety/efficacy • 2° Endpoint – adverse events/VCSS change

Almeida JI, Javier JJ, Mackay E et al. First human use of cyanoacrylate adhesive for treatment of saphenous veinincompetence. J Vasc Surg:Venous and Lym Dis 2013;1:174-80.

Page 15: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Results

• 1 year – 92% occlusion

• Volume – 1.3 ml.

• Phlebitis – 15%

• Thrombus extension – 21% (self limited) (5 cm back now)

• VCSS – 6.1 to 1.5

Page 16: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Most Recent Results: European Multicenter Study

• 70 GSV – No tumescence – No compression

• 7 Centers

• 94% occlusion at 6 months

• VCSS – 4.3 to 1.3

Proebstle T et al. One year follow up of the European Multicenter Study oncyanoacrylate embolization of incompetent great saphenous veins. UIP 2013.

Page 17: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

• Pharmaceutical-grade microfoam has been under development in Europe and the US for >12 years.

• Microfoam and the deliberate injection of gas into the venous circulation has presented unique challenges in demonstrating fundamental safety.

• A proprietary company has provided the experimental and trial data to answer important questions in relation to their specific microfoam O2, CO2, and trace N2

PEM: NTNT

Page 18: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

PEM: Polidocanol Endovenous MicrofoamVarithena™

• Status of trials- safe• Status of results – 75- 85%• GSV/SSV/VV/VM• Approved in US 12/13• Available in US momentarily

Polidocanol liquid

CO2/O2 gas

Microfoam generation mechanism

Page 19: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

PEM: Phase 3 Clinical TrialVANISH II

• 235 pts. – PLD .125%, .5%, 1% (176 pts.) – Placebo (59 pts.)

• PLD – 85% occlusion SFJ or GSV at 1 year

• Placebo – 20%

• Primary endpoint – pt. reported outcomes (VV SymQ)

• FDA approved QoL measure

Page 20: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Primary Endpoint: VV SymQ - Patient reported outcome for symptoms

Secondary Endpoints: PA-V3 Patient reported assessment of varicose vein appearance IPR-V3 Independent physician

photographic assessment of appearance (Both endpoints are new and have been developed to most recent FDA standards and outcome tested for clinically meaningfulness.)

Tertiary endpoint : Duplex closure (regarded as a surrogate endpoint )

VANISH II

Page 21: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

• Vanish 1 9.23 -5.44 (SE 0.29) 59% ↓p<0.0001

• Vanish 2 8.67 -5.53 (SE 0.33) 64% ↓p<0.0001

VV Sym Q: Symptoms

Page 22: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Results IPR-V3 (Independent MD)

Vanish 1 2.07 -0.81 (SE 0.05) 39% p<0.0001

Vanish 2 2.11 -0.86 (SE 0.06) 41% p<0.0001

Results PA-V3 (Patient reported VV)

Vanish 1 3.54 -1.58 (SE 0.09) 45% p<0.0001Vanish 2 3.54 -1.82(SE 0.09) 51% p<0.0001

Page 23: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

• Duplex response = elimination of SFJ reflux and /or closure of all incompetent veins

• Vanish 1 VV015, single treatment 75%

• Vanish 2 VV016, up to 2 treatments 85%

Closure Rates

Page 24: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Proximal DVT 1.7%•Dist CFV extension (EHIT 2 equivalent) 2.9%

– all completely resolved • (50% anticoagulated)

Distal DVT 1.1%IGSVT isolated gastroc/soleal 1.4%•No PE dx•No cerebrovascular neurological adverse events

Complications

Page 25: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

MOCA:NTNT

Page 26: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Position: Wire 1 cm SFJ

Page 27: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation
Page 28: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

MOCA: Mechanism of action

Page 29: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Elias FIM: Clinical Trial 2/09*

• 30 limbs• GSV only (no SSV, VV, IPV)• 1 yr. follow up to complete trial• No tumescence or sedation

*Elias S, Raines JK. Mechanochemical tumescentless endovenous ablation: final results of the initial clinical trial.Phlebology 2012;27:67-72.

Page 30: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Completed Trial and Non Trial*

•>2 years – 27/28 (96%) ( 1 died, 1 lost F/U)

•>2 years non trial – 29/30 (96%) (random pts.)

•VCSS – significant improvement at > 2 years

*Elias S, Lam YL, Wittens CHA. Mechanochemicalablation: status and results. Phlebology 2013 Supp. 1:28;10-14. .

Page 31: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Complications

• No DVT

• No nerve injury

• No skin injury

• Bruising 3 pts. - 2° caught on vein wall

Page 32: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

GSV Results: Dutch series• 224 GSV’s

• 6 weeks – 182/185 (98% closed)

• 6 months – 40/42 (95% closed)

• 1 year – 95% occlusion rate

• No nerve/skin injury or DVT*Ramon RJP, van Eekeren MD et al. Endovenous mechanochemical ablation ofgreat saphenous vein incompetence using the ClariVein device: a safety study.J Endovasc Ther 2011; 18:328-334.

*Reijnen M. One year results of MOCA. Charing Cross Meeting 2014. London

Page 33: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

SSV: 50 pts

• 1 yr. – 94% occlusion

• VCSS – 3 to 1

• No DVT, no nerve injury

Boersma D, van Eekeren RRJP, Werson DAB, et al.Mechanochemical endovenous ablation of smallsaphenous vein insufficiency using the ClariVeindevice: One-year results of a prospective series. EJVES2012.

Page 34: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

MOCA vs. RFMOCA

• 14 day pain – 8.6 (100)

• RTW – 3.3 days

• RT Activity – 1.2 days

• QoL - equal

RF• 14 day pain – 14.8 (100)

• RTW – 5.6 days

• RT Activity – 2.8 days

• QoL - equal

van Eekeren et al. Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenousablation of incompetent great saphenous veins. J VascSurg 2012.

Page 35: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

MOCA:Contraindications

• GSV/SSV – post SVT

• Synechiae – can place but wire snags

• Large veins - >15mm. (19mm)

Page 36: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Summary: MOCA

• >20,000 cases worldwide (GSV/SSV/AAGSV)• > 90% occlusion rate – various intervals• QoL – improves as any successful EVA• DVT - < 0.5% worldwide• No nerve injury

Page 37: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

V BLOCK: NTNT

Page 38: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

V Block

•Endovenous SFJ ligation

•Dual syringe system to deliver liquid sclerosant and empty vein

•Results - early

Page 39: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

V Block: SFJ Occlusion

Page 40: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

V Block: Dual Syringe

Page 41: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

V Block: Technique

Page 42: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

V Block: US Post insertion

Page 43: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

V Block: Early Results

• 50 patients

• 4.6 month avg. follow up

• 100% occlusion (46 pts.)

• Kolvenbach R. VEITH 2013

Page 44: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

NTNT: Special Considerations

• SSV, BK GSV, suprafascial – can go to malleolus

• C5 –C6 – antegrade (ankle) or retrograde tumescence hard to place

• AK GSV or AAGSV – of course

• Minimal nerve/skin injury

Page 45: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Endovenous Ablation: MEEVA

• Percutaneous, outpatient, local anesthesia

• TT:• RF/Laser - 95% ablation rate @ 4yrs• Steam - >90% at 1 year (Europe)

• NTNT : • MOCA – 95% ablation at >2 years• Foam – 85% at 2 years• Glue – 95% at 1 or less years• V Block – 100% at 4 months

Page 46: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

TT vs. NTNT (need both)

TT (10-15%)

• Big veins

• Good F/U

• Nerve - concern

• Patient comfort

NTNT (85-90%)

• Most GSV/SSV/C6/BK

• Shorter F/U

• Nerve – no issue

• Patient comfort: better?

Page 47: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

NTNT vs. TT:Eliminating Tumescence Is The Future

•TT – 14 years – time for something new•NTNT – nerve/skin risk less/patient comfort•Treat to malleolus/SSV•C5, C6 – tumescence difficult in lower leg•More complete treatment?•NTNT – The future (probably for 90% of EVA)

Page 48: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

THE END

• All new technologies positive impact QoL

• Simplify procedure = better for pt. and MD

• Current new technology: eliminate tumescence

• Future new technology: completely non invasive

Page 49: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

Before NTNT : mid 2000’s

Edward Hopper, Early Sunday Morning

Page 50: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

After NTNT: Last 5 years

Jackson Pollock, Number 1, 1949.

Page 51: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

“THE FUTURE OF NON THERMAL ABLATION:IS THE FUTURE OF ENDOVENOUS ABLATION”

Page 52: Future of Non Thermal Ablation: Is the Future of Endovenous Ablation

“Time will tell just who fellAnd who will be left behind

When you go your way and I go mine”

Dylan B. Most Likely To Go Your Way And I’ll Go Mine.